With an estimated 400 million people at risk for developing dementia, a natural remedy would be a welcome answer. That's the approach one British company is taking.
Nanonucleant, a spin-out of Imperial College London, is seeking angel financing to move ahead with a glass grain-based technology that aids in crystallising proteins for study as drug targets.
A microchip that mimics the function of the human brain could one day result in a mobile phone with the memory capacity of a desktop computer, researchers report.
Imperial College London's technology commercialisation company is betting on a spin-out company, deltaDOT, to speed detection and decrease costs of finding new proteins for drug discovery.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.